Immunomodulatory Effects of Afatinib and Pembrolizumab in EGFR-Mutant NSCLC with Progression on Prior EGFR-TKI

被引：2
|
作者：
Riess, J. [1 ]
Kelly, K. [1 ]
Schalper, K. [2 ]
Shimoda, M. [3 ]
Lim, S. [1 ]
Monjazeb, A. [1 ]
Danenberg, K. [4 ]
Moore, E. [1 ]
Beckett, L. [1 ]
Mack, P. [1 ]
Maverakis, E. [3 ]
Gandara, D. [1 ]
机构：
[1] Univ Calif Davis, Comprehens Canc Ctr, Sacramento, CA USA
[2] Yale Univ, Pathol, New Haven, CT USA
[3] Univ Calif Davis, Sch Med, Dermatol, Sacramento, CA USA
[4] Nanthealth, Liquid Genom, Torrance, CA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
immune microenvironment; EGFR-mutant NSCLC; Immunotherapy;
D O I：
10.1016/j.jtho.2018.08.724
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.04-09
引用
收藏
页码：S528 / S528
页数：1
相关论文
共 50 条
  • [1] Cytoplasmic ERβ expression to predict efficacy and survival of EGFR-TKI in EGFR-mutant NSCLC
    Wang, Zhijie
    Wang, Jie
    Wang, Xiaodong
    Shen, Zhirong
    Ding, Xiaosheng
    Bai, Hua
    Duan, Jianchun
    An, Tongtong
    Wang, Yuyan
    Zhuo, Minglei
    Wang, Shuhang
    Wu, Meina
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [2] A New Approach to Predict Progression-free Survival in Stage IV EGFR-mutant NSCLC Patients with EGFR-TKI Therapy
    Song, Jiangdian
    Shi, Jingyun
    Dong, Di
    Fang, Mengjie
    Zhong, Wenzhao
    Wang, Kun
    Wu, Ning
    Huang, Yanqi
    Liu, Zhenyu
    Cheng, Yue
    Gan, Yuncui
    Zhou, Yongzhao
    Zhou, Ping
    Chen, Bojiang
    Liang, Changhong
    Liu, Zaiyi
    Li, Weimin
    Tian, Jie
    [J]. CLINICAL CANCER RESEARCH, 2018, 24 (15) : 3583 - 3592
  • [3] Plasma microRNA signatures to predict EGFR-TKI resistance in EGFR-mutant advanced NSCLC patients.
    Wang, Shuhang
    Wang, Jie
    Bai, Hua
    An, Tongtong
    Zhao, Jun
    Wang, Zhijie
    Duan, Jianchun
    Zhuo, Minglei
    Wang, Yuyan
    Wu, Meina
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [4] Radiographic patterns of progression in patients with EGFR-mutant NSCLC undergoing EGFR TKI therapy.
    Brenner, Nicole
    Bastos, Bruno R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [5] Transglutaminase 2(TG2) induces the intrinsic EGFR-TKI resistance in EGFR-mutant NSCLC
    Choi, Junyoung
    Yang, Hannah
    Kim, Sang-We
    Jung, Kyung Hae
    Park, Kang-Seo
    Lee, Dae Ho
    [J]. CANCER RESEARCH, 2017, 77
  • [6] Efficacy, Safety and Dosage of Afatinib in Patients with NSCLC after Failure of Prior EGFR-TKI
    Kim, Young-Chul
    Choi, Hayoung
    Park, Cheol-Kyu
    Oh, In-Jae
    Yun, Ju-Sik
    Song, Sang-Yun
    Na, Kook-Joo
    Ahn, Sung-Ja
    Yoon, Mee Sun
    Choi, Yoo-Duk
    Seon, Hyun-Ju
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S647 - S647
  • [7] A Phase Ib Study of the Combination of Afatinib and Ruxolitinib in EGFR Mutant NSCLC Progressed on EGFR-TKI: An Updated Analysis
    Park, J. S.
    Hong, M. H.
    Cho, B. C.
    Kim, H. R.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1847 - S1847
  • [8] Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study
    Wenxian Wang
    Hong Wang
    Peihua Lu
    Zongyang Yu
    Chunwei Xu
    Wu Zhuang
    Zhengbo Song
    [J]. Journal of Translational Medicine, 17
  • [9] Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study
    Wang, Wenxian
    Wang, Hong
    Lu, Peihua
    Yu, Zongyang
    Xu, Chunwei
    Zhuang, Wu
    Song, Zhengbo
    [J]. JOURNAL OF TRANSLATIONAL MEDICINE, 2019, 17 (1)
  • [10] TATTON Ph Ib Expansion Cohort: Osimertinib plus Savolitinib for Pts with EGFR-Mutant MET-Amplified NSCLC after Progression on Prior EGFR-TKI
    Ahn, M.
    Han, J.
    Sequist, L.
    Cho, B. C.
    Lee, J. S.
    Kim, S.
    Su, W.
    Tsai, C.
    Yang, J. C.
    Yu, H.
    Horn, L.
    Lee, K.
    Haddad, V.
    Frigault, M.
    Ahmed, G.
    Yang, L.
    Ghiorghiu, D.
    Oxnard, G.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1768 - S1768
12345